Precision BioSciences

62 articles with Precision BioSciences

• Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

  12/6/2018

  SpaceX Falcon 9 Delivering ARCUS Gene Editing to the International Space Station

• Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

  11/27/2018

  Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR0191, an allogeneic anti-CD19 CAR T therapy for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

• Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

  11/14/2018

  Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology

• 

  Baltimore Longitudinal Study of Aging: How to Live Forever or Die Trying

  11/12/2018

  The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.

• Elo Life Systems Launches Australian Subsidiary in Queensland

  11/5/2018

  Elo Life Systems has opened a new Australian location at the Queensland University of Technology (QUT), Gardens Point Campus in Brisbane.

• Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

  9/12/2018

  Gilead Sciences and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.

• 

  Gilead News: Arthritis Drug, Precision BioSci Deal and Chief Medical Officer Change

  9/12/2018

  Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
• 

  Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

  9/10/2018

  In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”

• Precision Biosciences Announces Collaboration with University of Pennsylvania to Develop Genome Editing Therapeutics

  9/4/2018

  Precision BioSciences today announced an expansion of their ongoing collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania.

• 

  Precision BioSciences Closed on a $110 Million Series B Financing

  6/26/2018

  Precision BioSciences closed on an oversubscribed Series B financing worth $110 million. The funds will be used to continue developing its ARCUS genome editing platform.

• Precision BioSciences CSO to Join Gene Therapy Session at DIA 2018

  6/20/2018

  Precision BioSciences CSO Derek Jantz will present and join a panel discussion during the DIA (Drug Information Association) 2018 conference.

• Precision PlantSciences renamed Elo Life Systems

  6/4/2018

  Precision BioSciences has announced a new name and brand identity for its food and agriculture business.

• Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

  5/14/2018

  Precision BioSciences, the ARCUS genome editing company with novel product development programs in gene therapy, cancer immunotherapy and non-GMO food, will give three presentations at the upcoming ASGCT 21st Annual Meeting held in Chicago, Illinois, May 16-19, 2018.

• ACEA Biosciences Hosted Cancer and Immunotherapy Symposium for Leading Scientists in T Cell Therapy

  5/3/2018

  ACEA Biosciences, a biotechnology company that develops high performance cell analysis instruments, hosted their 6th annual Cancer Immunotherapy Symposium focused on CAR-T cell and TCR therapy on April 14, 2018 at the W Hotel in Chicago, prior to the 2018 AACR Annual Meeting.

• David Thomson Joins Precision BioSciences As Chief Development Officer

  7/10/2017

• Precision BioSciences Welcomes Fayaz Khazi, Ph.D. As President Of Plantsciences

  6/20/2017

• Precision BioSciences Release: Company Goes Paperless To Progress Innovation Using IDBS E-Workbook

  1/25/2017

• Baxalta Invests $1.6 Billion to Develop CAR-T Therapies with Precision BioSciences

  2/26/2016

• Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team

  9/2/2015

• Precision BioSciences Bags $25.6 Million Series A

  5/11/2015